Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

Literature DB >> 26243862

MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

Abstract

Clinical studies on MET-targeting cancer therapeutics have yielded mixed results in recent years, and MET-relevant predictive biomarkers remain elusive. New studies now reveal METex14 alternative splicing aberrations to represent potential predictive cancer genomic biomarker, hence renewing optimism and directions in the quest for optimized MET-targeting personalized cancer therapy. ©2015 American Association for Cancer Research.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2015 PMID： 26243862 PMCID： PMC4617658 DOI： 10.1158/2159-8290.CD-15-0769

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

11 in total

1. Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Authors: Monica Kong-Beltran; Somasekar Seshagiri; Jiping Zha; Wenjing Zhu; Kaumudi Bhawe; Nerissa Mendoza; Thomas Holcomb; Kanan Pujara; Jeremy Stinson; Ling Fu; Christophe Severin; Linda Rangell; Ralph Schwall; Lukas Amler; Dineli Wickramasinghe; Robert Yauch
Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701

2. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

Authors: Giorgio V Scagliotti; Silvia Novello; Joan H Schiller; Vera Hirsh; Lecia V Sequist; Jean-Charles Soria; Joachim von Pawel; Brian Schwartz; Reinhard Von Roemeling; Alan B Sandler
Journal: Clin Lung Cancer Date: 2012-03-21 Impact factor: 4.785

3. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors: Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal: Cancer Discov Date: 2015-05-13 Impact factor: 39.397

4. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Authors: Paul K Paik; Alexander Drilon; Pang-Dian Fan; Helena Yu; Natasha Rekhtman; Michelle S Ginsberg; Laetitia Borsu; Nikolaus Schultz; Michael F Berger; Charles M Rudin; Marc Ladanyi
Journal: Cancer Discov Date: 2015-05-13 Impact factor: 39.397

5. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Authors: Patrick C Ma; Ramasamy Jagadeeswaran; Simha Jagadeesh; Maria S Tretiakova; Vidya Nallasura; Edward A Fox; Mark Hansen; Erik Schaefer; Katsuhiko Naoki; Alan Lader; William Richards; David Sugarbaker; Aliya N Husain; James G Christensen; Ravi Salgia
Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701

Review 6. MET signaling: novel targeted inhibition and its clinical development in lung cancer.

Authors: Yan Feng; Praveena S Thiagarajan; Patrick C Ma
Journal: J Thorac Oncol Date: 2012-02 Impact factor: 15.609

7. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Authors: Patrick C Ma; Takashi Kijima; Gautam Maulik; Edward A Fox; Martin Sattler; James D Griffin; Bruce E Johnson; Ravi Salgia
Journal: Cancer Res Date: 2003-10-01 Impact factor: 12.701

8. Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer.

Authors: Yan Feng; Patrick C Ma
Journal: Cancer Discov Date: 2011-12 Impact factor: 39.397

Review 9. Hallmarks of cancer: the next generation.

Authors: Douglas Hanahan; Robert A Weinberg
Journal: Cell Date: 2011-03-04 Impact factor: 41.582

10. The landscape of kinase fusions in cancer.

Authors: Nicolas Stransky; Ethan Cerami; Stefanie Schalm; Joseph L Kim; Christoph Lengauer
Journal: Nat Commun Date: 2014-09-10 Impact factor: 14.919

14 in total

1. Special issue: "MET as actionable target in cancer therapy".

Authors: Patrick C Ma
Journal: Ann Transl Med Date: 2017-01

2. (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?

Authors: Patrick C Ma
Journal: Clin Cancer Res Date: 2019-02-15 Impact factor: 12.531

Review 3. Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors: Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal: Ann Transl Med Date: 2017-01

Review 4. MET/HGF pathway activation as a paradigm of resistance to targeted therapies.

Authors: Brian Ko; Tianfang He; Shirish Gadgeel; Balazs Halmos
Journal: Ann Transl Med Date: 2017-01

Review 5. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.

Authors: Anna Michelotti; Marco de Scordilli; Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Alessandra Bearz
Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208

Review 6. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.

Authors: Qiming Wang; Sen Yang; Kai Wang; Shi-Yong Sun
Journal: J Hematol Oncol Date: 2019-06-21 Impact factor: 17.388

7. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Authors: Valentina Martin; Cristina Chiriaco; Chiara Modica; Anna Acquadro; Marco Cortese; Francesco Galimi; Timothy Perera; Loretta Gammaitoni; Massimo Aglietta; Paolo M Comoglio; Elisa Vigna; Dario Sangiolo
Journal: Br J Cancer Date: 2019-02-06 Impact factor: 7.640